Compare Tapestry, Inc. (TPR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tapestry, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Tapestry, Inc. trades at $115.23 (market cap $22.87B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Tapestry, Inc. is far larger — about 4.7× Travere Therapeutics Inc. Common Stock's market cap, and Tapestry, Inc. pays a 1.61% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tapestry, Inc. for 70 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TPR | TVTX | |
|---|---|---|
Market Cap | $22.87B | $4.88B |
Volume | 1,963,570 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $164.78 | $67.52 |
52-Week Low | $98.81 | $26.79 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $25.67B | $5.01B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TPR trades at $115.03, down 1.87% today, with a neutral technical signal and bearish moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined to $183M. Recent earnings beats and a $174.64 consensus price target suggest upside potential. International growth in China and Europe supports fiscal 2027 expansion plans.
Outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and 52% upside to price target. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.85 P/E. Strong cash flow generation and Coach brand momentum provide fundamental support despite recent price weakness.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
